Ardian Set to Mobilize Development Finance Institutions (DFIs) With European Investment Bank (EIB), Proparco and British International Investment (BII) for a €100m Commitment for Its Nature-Based Solutions Strategy
Ardian, a world-leading private investment firm, today announces that it has secured commitment from several Development Finance Institutions (DFIs), the European Investment Bank (EIB) and Proparco. British International Investment (BII) have signaled their intention to provide commitment to the Nature Based Solutions fund. Total fund commitments will stand for a total of c. €100m by year end to Ardian’s Nature-Based Solutions (NBS) strategy. As anchor investors, EIB’s development arm EIB Global commits €50m, while Proparco will commit €20m and British International Investment has received approval for a €10m commitment, subject to final negotiations.
Averrhoa NBS is a SFDR1 Article 9 impact fund overseen by Ardian’s Infrastructure team in partnership with aDryada, a specialist developer and manager of large-scale ecosystem restoration projects. The strategy is dedicated to investing in projects to reforest and restore wetlands and mangroves, intended to protect biodiversity while enabling the sequestration of large volumes of carbon from the atmosphere via natural carbon sinks. The strategy aims to sequester 85 million tons of carbon over a period of 40 years2. These anchors investors, including FDJ UNITED for €5m and Mutuelle d’Ivry (La Fraternelle), will allow the fund to secure a €100m first round of commitment, and to attract institutional investors and corporate seeking to have positive environmental and social impact through their investment activities.
As well as sequestering carbon, Averrhoa NBS projects will seek to contribute to climate mitigation by preserving water resources and improving soil and air quality. The aim is to rebuild ecosystems and to protect natural habitats and biodiversity through richer and stronger ecosystems, as well as bringing sustainable income and investments in social infrastructures to local economies.
Over 50% of global GDP depends on healthy ecosystems, yet biodiversity loss is threatening economic stability, warns the World Bank. Forests are vanishing at 5 million hectares a year, while rising temperatures make the 1.5°C target harder to reach and are driving unprecedented species loss, endangering food security, climate resilience, water access, and public health.3 Ardian is contributing to address these challenges by developing high‑integrity, nature‑based carbon capture projects that also intend to restore biodiversity, benefit local communities, and support growing demand for credible net‑zero solutions.
Ardian strives to address a shortage of projects in this area. Large buyers are prioritizing nature-based solutions projects to achieve net zero due to their potential to restore biodiversity and create benefits for local communities.
Ardian’s NBS team has built a robust pipeline across Latin America, Africa and Asia through the careful selection of developers. Key criteria for project selection include a strong track record, a local team equipped for stringent monitoring, and advanced offtake discussions.
The NBS strategy forms a central part of Ardian’s broader decarbonization agenda. This track record includes financing 8.2GW of heat and renewable energy and its €2bn Hy24 hydrogen infrastructure fund. Ardian also provides capital solutions to companies committed to reducing their carbon footprint, with 11,000 portfolio companies committed to Science-based Target Initiative (SBTI) to support global net-zero target.
“This first €100m round of commitments marks a milestone in Ardian’s journey to becoming a -leading player in nature restoration projects. On top of targeting the sequestration of 85 million tons of carbon, the fund aims to play a significant role in restoring ecosystems, protecting biodiversity, while benefiting local communities. We are very grateful to our anchor investors for their confidence in Ardian’s world-class Infrastructure and NBS investment expertise.”
- LAURENT FAYOLLAS - MEMBER OF THE EXECUTIVE COMMITTEE AND DEPUTY HEAD OF INFRASTRUCTURE, ARDIAN
“This fund represents an important step forward in scaling nature-based solutions across emerging markets. We are helping to address climate change, protect biodiversity and improve the livelihoods of local communities. This investment reflects our commitment to mobilizing public and private capital for environmental protection and sustainable development.”
- AMBROISE FAYOLLE - VICE PRESIDENT, EIB
“As part of Proparco’s Natural Capital strategy, we are proud to partner with Ardian, aDryada, and the EU CarbonSinks Programme to support long-term investments in high-quality afforestation, reforestation, and revegetation projects. These initiatives will remove carbon from the atmosphere while also delivering strong climate, biodiversity, and socio-economic benefits for local communities.”
- JEAN-BAPTISTE SABATIÉ - DEPUTY CHIEF EXECUTIVE OFFICER, PROPARCO
“Supporting nature-based solutions is central to climate mitigation and adaptation, a cornerstone of BII’s climate strategy. At COP30, we reaffirm our commitment to mobilising capital for high impact projects that restore ecosystems and build climate resilience in emerging markets because tackling the climate emergency requires both innovation and scale.”
- LESLIE MAASDORP - CHIEF EXECUTIVE OFFICER, BRITISH INTERNATIONAL INVESTMENT
With Ardian clients and institutional investors increasingly prioritizing their contributions to biodiversity protection, Ardian’s Nature-Based Solutions strategy offers opportunities to invest in projects intended to enhance biodiversity, restore large-scale depleted ecosystems and support local economies.
Important notice: This press release is provided for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities or interests in any fund. Investments in private equity involve risks, including the risk of partial or total loss of capital. Any investment decision should be made solely on the basis of the fund’s official offering documentation. The fund referenced herein is intended exclusively for professional investors within the meaning of Directive 2014/65/EU or equivalent investor categories under the laws of the relevant jurisdictions.
1 Regulation (EU) 2019/2088 of the European Parliament and of the Council of 27 November 2019 on sustainability‐related disclosures in the financial services sector. The European Union sustainable-finance rules are still evolving. Hence, it cannot be excluded that future changes in law or guidance may not support the Fund’s current categorization under SFDR | |
| 2 Indicative figures based on current pipeline of project. Post ramp-up phase and assuming 40 years project life. | |
| 3 Damania, Richard; Ebadi, Ebad; Mayr, Kentaro; Russ, Jason; Zaveri, Esha. Reboot Development: The Economics of a Livable Planet. Washington, DC: World Bank, 2025. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20251112657727/en/
Contacts
Media Contacts
ARDIAN
HEADLAND
ardian@headlandconsultancy.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press Release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press Release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press Release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press Release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom